Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6092454 | 1.00 | MEN1 (0.38) | MEN1KMT2AHTR2CHTR2BPARP1 | |
| SCHEMBL6090599 | 0.90 | TNKS2 (0.35) | MEN1KMT2AHTR2CHTR2BPARP1 | |
| SCHEMBL6090604 | 0.90 | TNKS2 (0.35) | MEN1KMT2AHTR2CHTR2BPARP1 | |
| SCHEMBL6091162 | 0.89 | PARP1 (0.42) | HTR2CHTR2BPARP1KDM4EALDH1A1 | |
| SCHEMBL6090498 | 0.89 | TNKS2 (0.38) | MEN1KMT2AHTR2CHTR2BPARP1 | |
| SCHEMBL6090492 | 0.89 | TNKS2 (0.38) | MEN1KMT2AHTR2CHTR2BPARP1 | |
| SCHEMBL6091167 | 0.89 | PARP1 (0.42) | HTR2CHTR2BPARP1KDM4EALDH1A1 | |
| SCHEMBL6089898 | 0.86 | PARP1 (0.34) | HTR2CHTR2BPARP1KDM4EALDH1A1 | |
| SCHEMBL6089905 | 0.86 | PARP1 (0.34) | HTR2CHTR2BPARP1KDM4EALDH1A1 | |
| SCHEMBL6089474 | 0.85 | KDM4E (0.44) | MEN1KMT2AKDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-01-05 | — | — | US | disclosed |
| EP-1582520-A1 | NOVEL PARP INHIBITORS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004028-A1 | Novel PARP inhibitor | PARP1, PARP2, PARP11 | MEN1 2771/4885KMT2A 274/4885HTR2C 3206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.